Skip to main content
. 2017 Apr 18;8(26):42510–42524. doi: 10.18632/oncotarget.17207

Figure 3. Antitumor efficacy of YL001 in a xenograft tumor model.

Figure 3

(A) Tumor volume versus time after initial treatment with YL001 in B16 tumor-bearing mice. Columns, mean (n = 6); bars, SD. *P < 0.05. (B) Body weight versus days after initial treatment with YL001 in B16 tumor-bearing mice. Columns, mean (n = 6); bars, SD. (C) Percent survival versus time after implantation in B16 tumor-bearing mice treated with YL001 (n = 9). *P < 0.05. (D) H&E staining of a tumor from the control group. (E) H&E staining of a tumor from the YL001 treated group. (F) Pharmacokinetic study of YL001. Plasma concentration versus time after initial administration with YL001 in HeLa tumor-bearing Balb/c nude mice. Columns, mean (n = 3); bars, SD.